Loading
Convertible Plasma Jet / Breast Cancer · Interventional Study
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a recruiting, uncontrolled single-arm safety and dose-escalation study of non-thermal plasma applied to the tumor bed after breast cancer resection. No results are yet available in this registry record. The study aims to establish the maximum safe dose, assess tolerability, and document cosmetic effects over 3 months.
Interventional, Single Group, Open label, Other purpose. Breast Cancer; Female; age from 18 Years. Intervention: NTP treatment. n = 30. 1 site: Canada.
This is a recruiting, uncontrolled single-arm safety and dose-escalation study of non-thermal plasma applied to the tumor bed after breast cancer resection. No results are yet available in this registry record. The study aims to establish the maximum safe dose, assess tolerability, and document cosmetic effects over 3 months.
Single-arm design with no control group; cannot assess comparative efficacy or harm. Phase designation reported as 'NA'; unclear whether this is an early-phase safety study or preliminary feasibility work.
The source did not state who this applies to in practice.
This is a recruiting, uncontrolled, single-arm phase-agnostic safety and dose-escalation study with no published results; it is exploratory work in a novel intervention.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06222788). This is a study registration, not published results. Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM). Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 30 participants (ESTIMATED). Conditions: Breast Cancer. Interventions: DEVICE: Convertible Plasma Jet. Primary outcome measures: Incremental increase of NTP dose to reach maximum safe dose. , 3 months. Brief summary: The goal of this clinical trial is to test the safety of the use of non-thermal plasma (NTP, an ionized gas) on the tumor bed after the removal of the tumor in breast cancer patients. The main questions it aims to answer are: * To determine the safe and tolerable dose of NTP in patients with breast cancer; * To assess the safety and tolerability of NTP; * To assess the cosmetic effects of NTP treatment in patients with breast cancer. Participants will receive one treatment of the tumor bed after the removal of their breast tumor.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.